Postdoc: Translational Ribosome Biology in Pediatric Cancer

St. Anna Children's Cancer Research Institute (CCRI); Wien; On-site; EUR 42,000 - 54,000; Full time

Job summary

St. Anna Children's Cancer Research Institute (CCRI) in Vienna seeks a Postdoctoral researcher to investigate ribosome biology and translational control in pediatric cancers within the FWF Emerging Fields Consortium.

As part of a multidisciplinary team across six groups, you will apply genomics, proteomics, biochemical and structural approaches to decode cancer-specific translational regulation and identify novel therapeutic vulnerabilities in pediatric solid and hematologic cancers.

Qualifications

• PhD in molecular biology, cancer biology, biochemistry, molecular medicine, genomics, bioinformatics or structural biology.
• Strong scientific track record appropriate to career stage.
• Research experience relevant to pediatric cancer and ribosome biology.
• Strong interest in interdisciplinary and collaborative research.
• Ability to work independently while contributing to a team.
• Excellent written and spoken English.

Responsibilities

• Join one of the participating research groups within the Emerging Fields Consortium.
• Contribute to translational cancer biology and ribosome biology studies.
• Apply genomic, proteomic, biochemical and structural approaches.
• Map translational landscapes in pediatric cancer models.
• Collaborate across RNA biology, functional genomics, proteomics and structural biology.
• Publish findings and contribute to consortium objectives.

Skills

English

Education

PhD in molecular biology

Job description

St. Anna Children's Cancer Research Institute (CCRI) in Vienna seeks a Postdoctoral researcher to investigate ribosome biology and translational control in pediatric cancers within the FWF Emerging Fields Consortium.

As part of a multidisciplinary team across six groups, you will apply genomics, proteomics, biochemical and structural approaches to decode cancer-specific translational regulation and identify novel therapeutic vulnerabilities in pediatric solid and hematologic cancers.